The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab in patients (pts) with advanced gastrointestinal (GI) cancers with high plasma tumor mutational burden (pTMB): Results from a SCRUM-Japan GOZILA phase II trial.
 
Yoshiaki Nakamura
Honoraria - Chugai Pharma; Guardant Health AMEA; Merck
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Taito Esaki
Honoraria - Bristol-Myers Squibb Japan (Inst); Chugai Pharma; Daiichi Sankyo; Lilly; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Amgen Astellas BioPharma (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); DainipponSumitomo (Inst); DainipponSumitomo (Inst); Eisai (Inst); IQVIA (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Pfizer (Inst); Quintiles (Inst); Syneos Health (Inst)
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Ono Yakuhin; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sysmex (Inst); Takeda (Inst)
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
Research Funding - Chugai Pharma
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Shogo Nomura
Employment - Asahi Kasei (I)
Honoraria - AstraZeneca; Bayer; Chugai Pharma; Kyowa Hakko Bio
Research Funding - AstraZeneca (Inst)
 
Takashi Ikeno
No Relationships to Disclose
 
Yukiko Ishiguro
No Relationships to Disclose
 
Koji Takahashi
No Relationships to Disclose
 
Tsukiko Higuchi
No Relationships to Disclose
 
Akihiro Sato
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Pentax Medical Devices (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Justin Iver Odegaard
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Takeshi Kuwata
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb Japan; Daiichi Sankyo; FALCO biosystems; MSD; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo; Roche
Research Funding - Roche (Inst); Takeda (Inst)
 
Kouji Matsushima
Stock and Other Ownership Interests - Chemokine Frontier, Inc.; IDAC Theranostics; ImmunoGen
Research Funding - Kyowa Kirin (Inst); Ono Pharmaceutical (Inst)
 
Tetsuya Nakatsura
Stock and Other Ownership Interests - Noile-Immune Biotech, Inc
Consulting or Advisory Role - Takeda
Speakers' Bureau - Ono Pharmaceutical
Research Funding - BrightPath Biotheraputics (Inst); Daicel; Heartseed (Inst); LogoMix (Inst); Medinet (Inst); NA Vaccine Institute (Inst); Napajen Pharma (Inst); Ono Pharmaceutical (Inst); Optieum Biotechnologies Inc. (Inst); Resonac Corporation (Inst); Takara Bio (Inst); Thyas (Inst); Trans Chromosomics (Inst)
Patents, Royalties, Other Intellectual Property - Medinet; National Cancer Center Japan Thyas Co., Ltd.; Noile-Immune Biotech Inc.; OncoTherapy Science; Resonac Corporation; Sysmex; Takeda
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Genomedia (Inst); Molecular Health (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)